Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003).
Nov 9, 2016
Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
Nov 3, 2016
Data for Prothena's NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting